Biogen signs $2.1 billion Parkinson’s disease deal with DenaliBiogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in Share XBiogen signs $2.1 billion Parkinson’s disease deal with Denalihttps://pharmaphorum.com/news/biogen-signs-2-1-billion-parkinsons-disease-deal-with-denali/
F-star and Denali sign potential $1bn antibody dealDeal focuses on CNS bispecific antibodies. Share XF-star and Denali sign potential $1bn antibody dealhttps://pharmaphorum.com/news/f-star-star-denali-sign-potential-1bn-antibody-deal/